CLOs on the Move

Immunomedics

www.immunomedics.com

 
Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Ashok Marin
Vice President, Deputy General Counsel, Chief Compliance Officer and Chief Privacy Officer Profile
Ashok Marin
Vice President, Deputy General Counsel, Chief Compliance Officer and Chief Privacy Officer Profile
Jared Freedberg
General Counsel Profile
Jared Freedberg
General Counsel and Corporate Secretary Profile

Similar Companies

Bio Analytical Research Corporation

Bio Analytical Research Corporation is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Risdall Marketing Group

Risdall Marketing Group is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALOOKS SALON

ALOOKS SALON is a Pinole, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

emcresearch

emcresearch is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.